| Recent articles have included: |
 | Ductal carcinoma in situ of the breast – an overview of the randomized clinical trials
Ph. Meijnen, E. J. Th. Rutgers |
| Modelling and analysis of DCIS detection and reduction in invasive carcinoma - a review
S. W. Duffy |
| Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer
M. S. Frech, L. P. Jones, P. A. Furth |
| Minimally invasive approaches: cryoablation
T. L. Huston, R. M. Simmons |
| Implication of planned radiotherapy on breast reconstruction: radiotherapy and plastic surgery with implants
G. M. Freedman |
| Estrogen receptor acetylation and phosphorylation in hormone responses
C. Wang, M. Fu, R. G. Pestell |
| Shift in the surgical treatment of non-palpable breast cancer: tactile to visual
K. Dowlatshahi, J. Dieschbourg |
| New opportunities in premenopausal breast cancer: goserelin (‘Zoladex’) plus aromatase inhibition
R. Jakesz |
| Management of lesions first detected on MRI: what to do?
L. Bartella, E. A. Morris |
| The role of disseminated and circulating tumour cells in breast cancer
D. Auer, A. Schneitter, C. Marth, S. Braun |
| Therapeutic Mammotome excision of fibroadenomas
A. J. Maxwell |
| Role of plasma membrane ER protein in breast cancer
E. M. Rosen, S. Fan, Y. Ma, E. R. Levin |
| Accelerated partial breast irradiation: 3-dimensional conformal external beam radiotherapy
Y. Hasan, F. Vicini |
| The role of platinum-based therapy for HER-2-positive breast cancer
A. A. Joy, J. R. Mackey |
| Alcohol drinking and breast cancer
Duan-Jun Tan, Julie S. Barber, Peter G. Shields |
| Micrometastasis in lymph node
S. Masood |
| Pre-operative endocrine therapy: focus on the clinical and biological results of the IMPACT trial
R. L. Jones, I. E. Smith |
| Ultrasound elasticity imaging
W. E. Svensson, D. Amiras |
| Modest benefits of adjuvant chemotherapy in hormone receptor-positive breast cancer
Tiffany H. Svahn, Robert W. Carlson |
| Growth factor pathway switching: implications for the use of gefitinib and trastuzumab
H. E. Jones, JMW Gee, I.R. Hutcheson, RI Nicholson |
| The role of surgery for pulmonary metastases in breast cancer patients
D. A. Hess, H. M. Klomp |
| Should positive sentinel node cases have a further axillary dissection?
Blake Cady |
| Management of close margins in invasive breast cancer
R. J. Bleicher, M. Morrow |
| For the use of ultrasound by surgeons
J. Michael Dixon, E. Jane Macaskill |
| Can surgery provoke the outgrowth of latent breast cancer? A unifying hypothesis
M. W. Retsky, R. Demicheli, W. J. M. Hrushesky, M. Baum, I. D. Gukas |
| Positive sentinel lymph nodes should be followed by axillary lymph node dissection
F. Hoehne, H. Mabry, A. E. Giuliano |
| Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer
S. R. D. Johnston |
| Male breast cancer – how to treat?
E. D. Rossmann, A. Liljegren, J. Bergh |
| Integration of post-mastectomy radiation and breast reconstruction
J. L. Wright, P. G. Cordeiro, B. L. McCormick |
| Tamoxifen: using pharmacogenetics to rediscover an old drug
A. H. Kamal, M. P. Goetz |
| Breast cancer and pregnancy
G. K. Azad, A. E. Ring |
| Bisphosphonates and prevention of metastases: the AZURE study
R. Burkinshaw, H. Thorpe, R. Coleman |
| Indications for the sentinel node: multicentric, size of tumor, prior surgery
L. C. Hanker, A. Rody, E. Ruckhaeberle, M. Kaufmann |
| Therapeutic mammotome excisions: radial scars
J. Morel, M. J. Michell |
| Current status of adjuvant bisphosphonates in operable breast cancer
A. H. G. Paterson |
| Hypofractionated whole breast irradiation
John Yarnold |
| Update on chemoprevention in BRCA1 and BRCA2 mutation carriers
M. Stumacher, S. M. Domchek |
| Estrogen receptor acetylation and phosphorylation in hormone responses
C. Wang, M. Fu, R. G. Pestell |
| Applications of radiofrequency ablation in the treatment of breast cancer
S. Eva Singletary |
| What is breast density?
C. Byrne, S. Spernak |
| Screening for breast cancer in women with previous mantle radiotherapy for Hodgkin's disease
G. Ralleigh |
| COX-2 inhibitors in breast cancer
N. L. P. Barnes, N. J. Bundred |
| Bisphosphonates and the prevention of osteoporosis in the adjuvant setting
Michael Gnant |
| Breast cancer, stem cells, and the stem cell niche
G. Chepko |
| Aromatase inhibitors as adjuvant therapy: how will results of the ATAC trial at San Antonio 2004 and BIG 1-98 at St Gallen 2005 impact on aromatase inhibitors as adjuvant endocrine therapy?
N. S. Wong, K. I. Pritchard |
| Strategies to enhance radiosensitivity in breast cancer
S. C. Formenti |
| Skin-, nipple-, and areola-sparing mastectomy
E. M. Umoh, N. Arora, R. M. Simmons |
| The sexuality clinic in the breast center: sex as a survivorship issue
D. S. Dizon, D. Thompson, C. Duffy, D. Wiggins |
| Management of the intact breast primary in the setting of metastatic disease
H. Bermas, S. A. Khan |
| Delivering bad news: a vital skill for professionals involved in breast cancer care
M. N. Linver |
| Anti-angiogenic therapy: from laboratory to the patient
F. O. Ademuyiwa, G. W. Sledge Jr |
| Perioperative therapy in HER2+ patients
R. P. A’Hern, N. J. Bundred |
| Drugs targeting insulin-like growth factor 1 receptor
T. Mayer, L. Harris, M. P. DiGiovanna |
| Adjuvant endocrine therapy in premenopausal women with breast cancer
Michael Gnant, P. Dubsky, F. Fitzal, P. Blaha, G. Steger, R. Jakesz |
| Impact breast cancer has on family members/caregivers
L. Shockney |
